Actavis Confirms Generic Diprivan® Patent Challenge

             Actavis Confirms Generic Diprivan® Patent Challenge

PR Newswire

PARSIPPANY, N.J., June 7, 2013

PARSIPPANY, N.J., June 7, 2013 /PRNewswire/ --Actavis, Inc. (NYSE: ACT) today
confirmed that it has filed an Abbreviated New Drug Application (ANDA) with
the U.S. Food and Drug Administration (FDA) seeking approval to market
Propofol Injection 10mg/mL.Actavis' ANDA product is a generic version of
Fresenius Kabi's Diprivan^®, which is an intravenously administered sedative
and anesthetic.

Fresenius Kabi USA, LLC filed suit against Actavis on June 6, 2013, in the
U.S. District Court for the District of Delaware seeking to prevent Actavis
from commercializing its ANDA product prior to the expiration of certain U.S.
patents.The lawsuit was filed under the provisions of the Hatch-Waxman Act,
resulting in a stay of finalFDAapproval of Actavis' ANDA for up to 30 months
from the date the plaintiffs received notice of Actavis' ANDA filing or until
final resolution of the matter before the court, whichever occurs sooner,
subject to any other exclusivities.

For the 12 months ending April 30, 2013, brand and generic versions of
Diprivan^® had total U.S. sales of approximately $212 million according to IMS
Health data.

About Actavis

Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical
company focused on developing, manufacturing and distributing generic, brand
and biosimilar products.Actavis has global headquarters in Parsippany, New
Jersey, USA.

Operating as Actavis Pharma, Actavis develops, manufactures and markets
generic, branded generic, legacy brands and Over-the-Counter (OTC) products in
more than 60 countries.Actavis Specialty Brands is Actavis' global branded
specialty pharmaceutical business focused in the Urology and Women's Health
therapeutic categories.Actavis Specialty Brands also has a portfolio of five
biosimilar products in development in Women's Health and Oncology.Actavis
Global Operations has more than 30 manufacturing and distribution facilities
around the world, and includes Anda, Inc., a U.S. pharmaceutical product

For press release and other company information, visit Actavis' Web site at

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts
are forward-looking statements that reflect Actavis' current perspective of
existing information as of the date of this release. It is important to note
that Actavis' goals and expectations are not predictions of actual
performance. Actual results may differ materially from Actavis' current
expectations depending upon a number of factors, risks and uncertainties
affecting Actavis' business. These factors include, among others; the
difficulty of predicting the timing and outcome of the pending patent
litigation; the difficulty of predicting the timing or outcome of product
development efforts, including FDA and other regulatory agency approvals and
actions, if any; the impact of competitive products and pricing; the timing
and success of product launches; difficulties or delays in manufacturing; the
availability and pricing of third party sourced products and materials;
successful compliance with FDA and other governmental regulations applicable
to Actavis and its third party manufacturers' facilities, products and/or
businesses; changes in the laws and regulations; and such other risks and
uncertainties detailed in Actavis' periodic public filings with the Securities
and Exchange Commission, including but not limited to Actavis' Quarterly
Report on Form 10-Q for the quarter ended March 31, 2013 and Actavis' Annual
Report on form 10-K for the year ended December 31, 2012. Except as expressly
required by law, Actavis disclaims any intent or obligation to update these
forward-looking statements.

Diprivan^® is a registered trademark of Fresenius Kabi USA, LLC.

CONTACTS: Investors:
            Lisa DeFrancesco
            (862) 261-7152
            Charlie Mayr
            (862) 261-8030


SOURCE Actavis, Inc.

Press spacebar to pause and continue. Press esc to stop.